See every side of every news story
Published loading...Updated

Instylla Completes FDA PMA Submission for Embrace Hydrogel Embolic System - Endovascular Today

Summary by Endovascular Today
March 11, 2025—Instylla, Inc. announced that it recently submitted the final module of its premarket approval (PMA) application to the FDA for the company’s Embrace hydrogel embolic system (HES). According to Instylla, Embrace HES is an investigational device intended to embolize hypervascular tumors in vessels ≤ 5 mm. The company stated that the Embrace HES is composed of two injectable liquid precursors that solidify when simultaneously delive…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Endovascular Today broke the news in on Tuesday, March 11, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.